-

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

LYON, France--(BUSINESS WIRE)--Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).

“Efficacy of the STC-10101 a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003 https://doi.org/10.1158/1538-7445.AM2024-5003

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.

STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.

Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.

https://www.brenus-pharma.com/ | Follow us on LinkedIn

1 STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.
2 Brenus Pharma, Lyon, France,
3 INSERM U1194 IRCM, Montpellier, France,
4 CNRS 6302, Dijon, France,
5 Anaquant, Lyon, France
6 Inovotion, La Tronche, France,
7 Explicyte, Bordeaux, France
8 Inserm 1231 CGFL, Dijon, France

Contacts

mbrun@brenus-pharma.com | (+33) 787768772

Industry:

Brenus Pharma

Release Versions
English
Hashtags
#AACR2024
#Biotech
#Cancervaccine
#Clinical
#Colorectalcancer
#Healthcare
#Immunotherapy

Contacts

mbrun@brenus-pharma.com | (+33) 787768772

Social Media Profiles
Follow Brenus Pharma
More News From Brenus Pharma

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

LYON, France--(BUSINESS WIRE)--Brenus Pharma today announced that first patients have been successfully dosed in its first-in-human clinical trial evaluating STC-1010, the company’s lead in vivo immunotherapy candidate developed through its proprietary off-the-shelf platform. Three patients have already been enrolled in the study. The first completed eight weeks of treatment with no adverse events attributed to the investigational therapy. This trial targets patients with unresectable, locally...

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy

LISBON, Portugal--(BUSINESS WIRE)--Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer. Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorect...

AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a French clinical-stage biotechnology company, presented new preclinical data on its lead immunotherapy candidate, STC-1010, during the Late-Breaking Research: Immunology 3 session at the AACR Annual Meeting 2025, held April 25–30 in Chicago, IL. The data highlight advances from Brenus Pharma’s proprietary Stimulated-Tumor-Ghost Cell (SGC) platform, a next-generation precision immuno-oncology approach showcasing its potential to initiate a robust an...
Back to Newsroom